Moderna, a frontrunner in the biotech sector, has received full U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, for children aged 6 months through 11 years at increased risk for COVID-19 disease. With its stock prices rising as a response, it reflects the confidence market keeps in the company. The company continues its innovation streak by working towards a combo Covid and flu shot which reportedly outperforms current vaccines in large trials, reflecting promising efficacy results. However, it also faces challenges, as Pfizer and BioNTech are seeking to overturn Moderna's Corona vaccine patent win in the UK. The negative news includes cancellation of funding by the HHS for Moderna’s H5 avian flu and pandemic vaccines. Despite some setbacks, Moderna has remained proactive and ambitious about its growth and innovation prospects with efforts for pandemic preparedness and creating vaccines beyond Covid.
Moderna MRNA News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sat, 12 Jul 2025 23:19:17 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 8
